osteoblast

Osteoblasts arise from mesenchymal stem cells (via RUNX2 and Osterix transcription factors) and are located on bone surfaces. They secrete type I collagen, osteocalcin, osteopontin, and alkaline phosphatase, forming osteoid that later mineralizes with hydroxyapatite. Osteoblasts express RANKL on their surface, which binds RANK on osteoclast precursors to stimulate osteoclast differentiation and bone resorption; they also secrete osteoprotegerin (OPG), a decoy receptor that inhibits this process—this RANKL/OPG ratio is central to bone remodeling homeostasis. PTH has a dual effect: continuous exposure increases RANKL expression (favoring resorption), while intermittent PTH (as in teriparatide therapy) promotes osteoblastic bone formation. Vitamin D (calcitriol) stimulates osteoblast differentiation and mineralization. Estrogen deficiency (e.g., menopause) reduces OPG and increases RANKL, tipping the balance toward resorption—key in osteoporosis pathogenesis. Osteoblasts can become embedded in matrix and differentiate into osteocytes, which sense mechanical stress and regulate remodeling via sclerostin (inhibits Wnt signaling, thus inhibiting osteoblast activity). Clinically relevant: osteoblastic activity is measured by serum alkaline phosphatase and osteocalcin; osteoblastic bone lesions occur in prostate cancer metastases; bisphosphonates and denosumab (anti-RANKL antibody) target the RANKL-osteoclast axis, while teriparatide is an anabolic (osteoblast-stimulating) osteoporosis therapy. Understanding this pathway is essential for USMLE questions on osteoporosis, hyperparathyroidism, Paget disease, and osteopetrosis.